Abstract
In healthy subjects, LX1033 produced similar reductions in u5-HIAA, compared to the first generation SSI (LX1031), at lower doses. LX1033 has the potential to improve IBS-D symptom response at lower doses compared to Lexicon’s first generation SSI, LX1031. Correlation between urine and plasma 5-HIAA may allow for a potential easy to measure blood marker to guide IBS-D therapy. LX1033 has been advanced into clinical trials in patients with IBS-D.
